GE Healthcare and Promosome Sign Licensing Agreement - - BioPharm International

ADVERTISEMENT

GE Healthcare and Promosome Sign Licensing Agreement



GE Healthcare and Promosome LLC, a synthetic biology company, have signed a licensing agreement, giving GE Healthcare exclusive rights to a new suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.

In-licensing of Promosome’s cell line development technologies will enable GE Healthcare to expand its offering with a cell-line generation service focused on delivering increased expression levels for hard-to-manufacture therapeutic proteins and improving manufacturing efficiency through increased protein yields.

GE Healthcare recently acquired Thermo Fisher’s HyClone cell culture media and sera business.

Source: GE Healthcare

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here